Navigation Links
A new indicator for breast cancer relapse identified

This press release is available in Spanish.

Researchers at the IMIM (Institut de Recerca Hospital del Mar) have proven that the absence of the 14-3-3 protein sigma in breast cancer cells is directly associated with these cells' capacity to activate the signalling of a protein complex called NF-kB, which is related to tumour progression. The activation of NF-kB in tumours was also identified as the best indicator for relapse in breast cancer patients, compared to other parameters currently used, such as the presence of affected ganglions or the tumour's size and degree. The investigators have also described a group of genes that are activated in breast cancer cells and that are also associated with a poor prognosis in other types of tumours.

Previous studies had detected that the 14-3-3 protein sigma was not present in the tumours of many breast cancer patients. They have now discovered that 'the lack of this protein does not in itself establish a prognosis factor for these types of cancer, although the NF-kB complex is an essential requirement for it to remain active chronically, as it is associated with tumour invasion and metastasis or, stated differently, the progression of the tumour', comments Llus Espinosa, study coordinator and researcher in the IMIM stem cells and cancer research group.

Breast cancer is most common among women in Western countries and relapse and metastasis are the fatal consequences of this disease. Identifying the mechanisms involved in the survival of breast cancer cells and their ability to colonise other tissues are crucial issues for improving treatment. With the participation of some 100 patients, this study analysed the possible usefulness of determining the lack of the 14-3-3 sigma and/or the activation of NF-kB in tumour cells as a factor in prognosis and diagnosis, as well as for future clinical and therapeutic applications.

The results obtained from this project have opened up new roads of investigation that will have to centre on identifying the pharmaceuticals that induce the expression of the 14-3-3 protein sigma in breast tumours and characterise their effect on tumour cells. They also hope to define which genes activated by the NF-kB complex are important for tumour progression in this group of patients and to study their potential as possible therapeutic targets.

According to Espinosa 'This opens up the possibility of researching and employing specific therapeutic strategies for this concrete group of patients who, in principle, have bad prognoses and an especially high risk of relapse'.

The study was initially led and developed at the IMIM by Dr Llus Espinosa's and Anna Bigas' group and collaboration from researchers and doctors from the Hospital del Mar, the Jimenez Daz Foundation, the Barcelona Institute of Biomedical Research (IRB) and Pompeu Fabra University.

Contact: Marta Calsina
IMIM (Hospital del Mar Research Institute)

Related biology news :

1. AAO-HNS releases updated Clinical Indicators
2. Researchers identify need to sample multiple tumor zones in breast cancer
3. UCSB anthropologists finds high levels of omega-3 fatty acids in breast milk of Amerindian women
4. Cardio fitness levels of breast cancer patients may affect survival
5. Newly discovered breast milk antibodies help neutralize HIV
6. Breast-fed babies gut microbes contribute to healthy immune systems
7. Heparin-like compounds inhibit breast cancer metastasis to bone
8. Blocking DNA: HDAC inhibitor targets triple negative breast cancer
9. Study sheds new light on importance of human breast milk ingredient
10. Molecule found that inhibits estrogen, key risk factor for endometrial and breast cancers
11. MicroRNA controls malignancy and resistance of breast cancer cells
Post Your Comments:
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted ... quarter of 2015 The gross margin was 49% (27) ... the operating margin was 40% (-13) Earnings per share ... operations was SEK 249.9 M (21.2) , Outlook   ... M. The operating margin for 2016 is estimated to ...
(Date:4/15/2016)...  A new partnership announced today will help ... in a fraction of the time it takes ... life insurance policies to consumers without requiring inconvenient ... Diagnostics, rapid testing (A1C, Cotinine and HIV) and ... weight, pulse, BMI, and activity data) available at ...
(Date:3/31/2016)... 2016   LegacyXChange, ... "Company") LegacyXChange is excited to release its ... to be launched online site for trading 100% guaranteed ... will also provide potential shareholders a sense of the ... an industry that is notorious for fraud. The video ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... -- Global demand for enzymes is forecast to grow ... billion.  This market includes enzymes used in industrial ... animal feed, and other markets) and specialty applications ... beverages will remain the largest market for enzymes, ... containing enzymes in developing regions.  These and other ...
(Date:6/27/2016)... , ... June 27, 2016 , ... Parallel 6 ... trials, announced today the Clinical Reach Virtual Patient Encounter CONSULT module which ... with the physician and clinical trial team. , Using the CONSULT module, patients and ...
(Date:6/27/2016)... , June 27, 2016   Ginkgo Bioworks ... to industrial engineering, was today awarded as one ... selection of the world,s most innovative companies. Ginkgo ... scale for the real world in the nutrition, ... engineers work directly with customers including Fortune 500 ...
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita ... miRNAs in people with peritoneal or pleural mesothelioma. Their findings are the subject of ... now. , Diagnostic biomarkers are signposts in the blood, lung fluid or tissue ...
Breaking Biology Technology: